Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
FARMINGTON HILLS, Mich., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
-
Durability of Nyxol’s Pupil Constricting Effects Using an Evening Dosing Regimen Informs Dosing Strategy for Phase 2 Trial in Presbyopia and Phase 3 Trial in NVD Ocuphire Invited to Present at the...
-
Nyxol has Potential to be a New Treatment Option for Reversal of Pharmacologically-Induced Pupil Dilation Top-Line Data for MIRA-2 Expected by End of Q1 2021 FARMINGTON HILLS, Mich.,...
-
Nyxol is in Late Stage Clinical Development for A New Ophthalmic Indication Top Line Data from LYNX-1 Expected 3Q2021 FARMINGTON HILLS, Mich., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Ocuphire...
-
FARMINGTON HILLS, Mich., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the...
-
FARMINGTON HILLS, Mich., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the...
-
Begins Enrollment in the First of Four Upcoming Late-Stage Trials in the U.S. Announces MIRA-1 Phase 2b Study Accepted for Peer-Reviewed Publication in Optometry and Vision Science FARMINGTON HILLS,...
-
Allowed Japanese Patent Application for Daily Ophthalmic Use of Nyxol to Improve Visual Performance R&D Funding for APX3330 and Pipeline Candidates with $1.7M NIH National Eye Institute Grant ...
-
FARMINGTON HILLS, Mich., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc., (Nasdaq: OCUP) a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
-
FARMINGTON HILLS, Mich., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the...